The latest call
FetchingFortress Biotech, Inc. reported on November 13, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Loading company
Fortress Biotech, Inc.
FBIO · Nasdaq · ·
$1.88-5.3%Nov 13 close
The latest quarter (ended September 30, 2026) is from Fortress Biotech’s earnings press release of November 13, 2026. It will be replaced by the official quarterly report (10-Q) once Fortress Biotech files it.
Past performance
- 1W
- +1.4%
- 1M
- -1.3%
Just reported
Q3 2026 results
From Fortress Biotech, Inc.'s results release of November 13, 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
$19.2M
+8.7% y/y
+2.4% q/qGuided
—
No guide given
Operating income, GAAP
Actual
-$7.2M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $19.2M | $17.6M | +8.67% |
| Profit | -$5.8M | $5.9M | -199.91% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
What Fortress Biotech, Inc. does
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Institute and Sentynl Therapeutics.
The company’s own description, as it appears at the foot of the release.
The quote, the company description and the latest quarter come from Fortress Biotech’s earnings press release (an Item 2.02 8-K) filed November 13, 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Read the release on EDGAR Share prices are split- and dividend-adjusted.